During the recent session, Sensei Biotherapeutics Inc (NASDAQ:SNSE)’s traded shares were 53.2 million, with the beta value of the company hitting 0.16. At the last check today, the stock’s price was $0.66, reflecting an intraday gain of 53.48% or $0.23. The 52-week high for the SNSE share is $1.94, that puts it down -193.94 from that peak though still a striking 42.42% gain since the share price plummeted to a 52-week low of $0.38. The company’s market capitalization is $16.64M, and the average intraday trading volume over the past 10 days was 1.04 million shares, and the average trade volume was 501.51K shares over the past three months.
Sensei Biotherapeutics Inc (SNSE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SNSE has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.29.
Sensei Biotherapeutics Inc (NASDAQ:SNSE) trade information
Sensei Biotherapeutics Inc (SNSE) registered a 53.48% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 53.48% in intraday trading to $0.66, hitting a weekly high. The stock’s 5-day price performance is 34.94%, and it has moved by 50.62% in 30 days. Based on these gigs, the overall price performance for the year is -36.42%. The short interest in Sensei Biotherapeutics Inc (NASDAQ:SNSE) is 0.12 million shares and it means that shorts have 1.42 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 88.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $6 respectively. As a result, SNSE is trading at a discount of -809.09% off the target high and -657.58% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -16.26%. While earnings are projected to return 47.22% in 2025, the next five years will return 13.38% per annum.
SNSE Dividends
Sensei Biotherapeutics Inc is due to release its next quarterly earnings on 2024-Nov-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sensei Biotherapeutics Inc (NASDAQ:SNSE)’s Major holders
Sensei Biotherapeutics Inc insiders own 34.22% of total outstanding shares while institutional holders control 9.37%, with the float percentage being 14.25%. IKARIAN CAPITAL, LLC is the largest shareholder of the company, while 27.0 institutions own stock in it. As of 2024-06-30, the company held over 0.65 million shares (or 2.5949% of all shares), a total value of $0.4 million in shares.
The next largest institutional holding, with 0.62 million shares, is of VANGUARD GROUP INC’s that is approximately 2.4702% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.38 million.
Also, the Mutual Funds coming in first place with the largest holdings of Sensei Biotherapeutics Inc (SNSE) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund. Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 485.96 shares. This amounts to just over 1.93 percent of the company’s overall shares, with a $0.34 million market value. The same data shows that the other fund manager holds slightly less at 99.62, or about 0.40% of the stock, which is worth about $68794.0.
